Ticagrelor - Latest Advances

Ticagrelor plus aspirin versus cilostazol plus aspirin in the acute-phase treatment of large-vessel minor stroke or TIA: a randomized controlled multi-center trial, the TACTIS trial.

Journal: International journal of stroke : official journal of the International Stroke Society

Published: December 02, 2025

Study protocol for low-dose evaluation of aspirin in patients with ST-elevation myocardial infarction undergoing percutaneous coronary intervention (LEAST): a multicenter, double-blind, randomized controlled clinical trial.

Journal: Annals of medicine

Published: November 24, 2025

Genetic Determinants of Response to P2Y12 Inhibitors and Clinical Implications.

Journal: Heart failure clinics

Published: November 20, 2025

Bioavailability Enhancement and Polymorphic Stabilization of One BCS Class IV Metastable Drug Through Novel Formulation Approach.

Journal: Turkish journal of pharmaceutical sciences

Published: November 18, 2025

Impact of dual antiplatelet therapy within 72 hours post mild ischemic stroke and transient ischemic attack: meta-analysis.

Journal: Brain injury

Published: November 18, 2025

Prolonged dual antiplatelet therapy with ticagrelor 60 mg twice daily in patients with a prior myocardial infarction: real-world insights on incidence and reasons for non-compliance.

Journal: Minerva cardiology and angiology

Published: November 13, 2025

Evaluation of the Anti-inflammatory Effects of Ticagrelor and Prasugrel as Add-On Therapy to Aspirin in Diabetic Patients Post-percutaneous Coronary Intervention.

Journal: Cureus

Published: November 09, 2025

Safety and Efficacy of Ticagrelor-Based Dual Antiplatelet Therapy in Endovascular Treatment of Unruptured Intracranial Aneurysms: A Large Single-Center Retrospective Study.

Journal: Cardiovascular and interventional radiology

Published: November 07, 2025

Reduction of Thrombus Burden With Short-Term, Low-Dose Rivaroxaban Use in Acute Myocardial Infarction: The ARISE-ARMYDA 7 Randomized Trial.

Journal: Journal of the American Heart Association

Published: November 06, 2025

Immunomodulatory Effects of Ticagrelor in Myocardial Infarction: Shifting the Cytokine Balance Toward an Anti-Inflammatory Profile.

Journal: Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research

Published: November 05, 2025

Comparative Effects of P2Y12 Inhibitors on Thrombus Biology and Inflammatory Responses in Atherothrombotic Cardiovascular Disease: A Systematic Review of Randomized Controlled Trials.

Journal: Cureus

Published: October 31, 2025

Comparison of in-hospital net clinical outcomes of ticagrelor and clopidogrel in acute coronary syndrome patients stratified by CRUSADE score: findings from the CCC-ACS registry.

Journal: Platelets

Published: October 27, 2025

Filters

Ticagrelor plus aspirin versus cilostazol plus aspirin in the acute-phase treatment of large-vessel minor stroke or TIA: a randomized controlled multi-center trial, the TACTIS trial.

Ticagrelor plus aspirin versus cilostazol plus aspirin in the acute-phase treatment of large-vessel minor stroke or TIA: a randomized controlled multi-center trial, the TACTIS trial.

Study protocol for low-dose evaluation of aspirin in patients with ST-elevation myocardial infarction undergoing percutaneous coronary intervention (LEAST): a multicenter, double-blind, randomized controlled clinical trial.

Study protocol for low-dose evaluation of aspirin in patients with ST-elevation myocardial infarction undergoing percutaneous coronary intervention (LEAST): a multicenter, double-blind, randomized controlled clinical trial.

Genetic Determinants of Response to P2Y12 Inhibitors and Clinical Implications.

Genetic Determinants of Response to P2Y12 Inhibitors and Clinical Implications.

Bioavailability Enhancement and Polymorphic Stabilization of One BCS Class IV Metastable Drug Through Novel Formulation Approach.

Bioavailability Enhancement and Polymorphic Stabilization of One BCS Class IV Metastable Drug Through Novel Formulation Approach.

Impact of dual antiplatelet therapy within 72 hours post mild ischemic stroke and transient ischemic attack: meta-analysis.

Impact of dual antiplatelet therapy within 72 hours post mild ischemic stroke and transient ischemic attack: meta-analysis.

Prolonged dual antiplatelet therapy with ticagrelor 60 mg twice daily in patients with a prior myocardial infarction: real-world insights on incidence and reasons for non-compliance.

Prolonged dual antiplatelet therapy with ticagrelor 60 mg twice daily in patients with a prior myocardial infarction: real-world insights on incidence and reasons for non-compliance.

Evaluation of the Anti-inflammatory Effects of Ticagrelor and Prasugrel as Add-On Therapy to Aspirin in Diabetic Patients Post-percutaneous Coronary Intervention.

Evaluation of the Anti-inflammatory Effects of Ticagrelor and Prasugrel as Add-On Therapy to Aspirin in Diabetic Patients Post-percutaneous Coronary Intervention.

Safety and Efficacy of Ticagrelor-Based Dual Antiplatelet Therapy in Endovascular Treatment of Unruptured Intracranial Aneurysms: A Large Single-Center Retrospective Study.

Safety and Efficacy of Ticagrelor-Based Dual Antiplatelet Therapy in Endovascular Treatment of Unruptured Intracranial Aneurysms: A Large Single-Center Retrospective Study.

Reduction of Thrombus Burden With Short-Term, Low-Dose Rivaroxaban Use in Acute Myocardial Infarction: The ARISE-ARMYDA 7 Randomized Trial.

Reduction of Thrombus Burden With Short-Term, Low-Dose Rivaroxaban Use in Acute Myocardial Infarction: The ARISE-ARMYDA 7 Randomized Trial.

Immunomodulatory Effects of Ticagrelor in Myocardial Infarction: Shifting the Cytokine Balance Toward an Anti-Inflammatory Profile.

Immunomodulatory Effects of Ticagrelor in Myocardial Infarction: Shifting the Cytokine Balance Toward an Anti-Inflammatory Profile.

Comparative Effects of P2Y12 Inhibitors on Thrombus Biology and Inflammatory Responses in Atherothrombotic Cardiovascular Disease: A Systematic Review of Randomized Controlled Trials.

Comparative Effects of P2Y12 Inhibitors on Thrombus Biology and Inflammatory Responses in Atherothrombotic Cardiovascular Disease: A Systematic Review of Randomized Controlled Trials.

Comparison of in-hospital net clinical outcomes of ticagrelor and clopidogrel in acute coronary syndrome patients stratified by CRUSADE score: findings from the CCC-ACS registry.

Comparison of in-hospital net clinical outcomes of ticagrelor and clopidogrel in acute coronary syndrome patients stratified by CRUSADE score: findings from the CCC-ACS registry.